-
Using C3d Staining to Identify Complement-mediated Hemolytic Uremic Syndrome in Kidney Biopsies
Rochester, MN
The aim of this project is to evaluate whether kidney biopsy tissue will stain positive for C3d under immunofluorescence in patients who had renal thrombotic microangiopathy (TMA) caused by atypical hemolytic uremic syndrome (aHUS) and to study if that could offer a diagnostic value.
-
A Study to Assess the Updated Prospera™ Diagnostic Test
Scottsdale/Phoenix, AZ
The purpose of this study to collect blood samples and data to assess the diagnostic capability of an updated version of the Prospera™ test. The current standard of care for detection of rejection in renal allograft recipients is serum creatinine, often used in combination with other blood tests such as proteinuria. Natera has developed an assay called Prospera™ to detect the amount of donor-derived cell-free DNA (dd-cfDNA), which is a marker of kidney rejection.
-
A Study to Evaluate Kidney Care and HistoMap in Microvascular Inflammation
Scottsdale/Phoenix, AZ
The purpose of this study is to evaluate KidneyCare (AlloSure, AlloMap kidney and iBox) in patients with negative c4d microvascular inflammation (MVI) with or without Donor-Specific Antibodies (DSA) as compared to cohort with normal biopsies without DSA.
-
A Study to Assess Reproductive History in Kidney Donors
Scottsdale/Phoenix, AZ; Rochester, MN
The purpose of this study is to analyze the effect of parity, menopause and reproductive lifespan on kidney structure and function.
-
A Study To Predict Response To Virotherapy And Immunotherapy By Using An Ex-Vivo Three-Dimensional Patient-Derived Organoid Model Of Pediatric Urological Cancers
Rochester, MN
The purpose of this study is threefold: the first aim is to use patient-derived fresh tumor tissue to create cell lines and 3D tumor models (i.e. organoids) that preserve the characteristics of the original tumor. The preservation of the original tumor's drug resistance/response profile will be a major focus of this aim. The second aim is to conduct high-throughput testing of various drugs (e.g., virotherapy, immunotherapy) on these cell lines and 3D tumor models. The completion of the second aim is an important step towards developing a platform that can help guide treatment decisions for future patients, based on the drug ...